ArticleFrontiers in medicine2025
Serum matrix metalloproteinase-9 levels and enzymatic activity in patients with anti-glomerular basement membrane disease.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Mechanism and Application of Traditional Chinese Medicine Nano-Formulations in the Treatment of Renal Fibrosis.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-glomerular basement membrane (anti-GBM) disease is an autoimmune disorder with autoantibodies against GBM component, non-collagenous domain of the α3 chain of type IV collagen, α3(IV)NC1. Matrix metalloproteinase-9 (MMP-9) is an endogenous enzyme for the degradation of GBM to produce α3(IV)NC1. The current study was aimed to investigate the serum levels and enzymatic activity of MMP-9 and their clinical significance in patients with anti-GBM disease. Methods: MMP-9 serum levels and enzymatic activity were measured by enzyme-linked immunosorbent assay in 77 patients with anti-GBM disease and 20 healthy individuals. The association of MMP-9 levels and enzymatic activity with clinical-pathological features of patients was analyzed. Results: MMP-9 levels and enzymatic activity were elevated in 53.2% (41/77) and 61.0% (47/77) of patients with anti-GBM disease, and in 0% (0/20) and 10% (2/20) of healthy individuals ( Conclusion: The serum MMP-9 levels and enzymatic activity were elevated in patients with anti-GBM disease. The association between MMP-9 activity and clinical-pathological features indicated that MMP-9 might play different roles in disease development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.